FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200416268> ?p ?o ?g. }

• W4200416268 abstract "Abstract Several biologic treatments are available in addition to intravenous also in subcutaneous form for treatment of chronic diseases. Benefits of the subcutaneous application of drugs include self-administration by the patient, shorter time of application process with less infusion related adverse events and consequently lower healthcare costs. With appropriate education and support patients are able to administer their treatments at home. This leads to improvement of quality of life, reduction of time needed to travel to the healthcare institution and consequently also reduces costs also for the patient. Over one million residents in the USA and 2.5 million in Europe are estimated to have inflammatory bowel disease (IBD), with substantial costs for health care. These estimates do not factor in the ‘real’ price of IBD, which can impede career aspirations, instil social stigma and impair quality of life in patients. The Virtual Community Meeting, which offered an exchange of experience and opinions from healthcare professionals who are active in treating IBD, and patients with this chronic disease, revealed in-depth arguments and answers to some essential questions: which patients prefer subcutaneous over intravenous dosing; which patients continue to favour intravenous infusions; what are the limitations regarding both applications; what is the patient’s role in therapeutical decision-making and how does IBD affect the patient’s work, finances and quality of life? The aim of this article is to discuss the differences between subcutaneous and intravenous dosing from the health-economic, scientific, and personal perspectives. The meeting offered strong confirmation that most of the patients and healthcare professionals prefer subcutaneous over intravenous drug administration but emphasise the management of risks associated with treatment compliance. Patient education provided by the IBD team in this regard is mandatory. Quality of life of patients is poorer during active disease, but the findings that it can improve over time, including as a result of home- or self-administration of biologics, may be encouraging for individuals with this chronic disease." @default.
• W4200416268 created "2021-12-31" @default.
• W4200416268 creator A5002432376 @default.
• W4200416268 creator A5012265328 @default.
• W4200416268 creator A5026802895 @default.
• W4200416268 creator A5033719787 @default.
• W4200416268 creator A5046857018 @default.
• W4200416268 creator A5049187164 @default.
• W4200416268 creator A5056683017 @default.
• W4200416268 creator A5066028867 @default.
• W4200416268 creator A5068388301 @default.
• W4200416268 creator A5069553267 @default.
• W4200416268 creator A5076170209 @default.
• W4200416268 creator A5076522769 @default.
• W4200416268 creator A5077260044 @default.
• W4200416268 creator A5081498298 @default.
• W4200416268 creator A5084212600 @default.
• W4200416268 creator A5085954137 @default.
• W4200416268 creator A5090767185 @default.
• W4200416268 date "2021-12-01" @default.
• W4200416268 modified "2023-10-15" @default.
• W4200416268 title "Intravenous versus subcutaneous delivery of biotherapeutics in IBD: an expert’s and patient’s perspective" @default.
• W4200416268 cites W2102567329 @default.
• W4200416268 cites W2803673833 @default.
• W4200416268 cites W2883052264 @default.
• W4200416268 cites W2899003764 @default.
• W4200416268 doi "https://doi.org/10.1186/s12919-021-00230-7" @default.
• W4200416268 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34879868" @default.
• W4200416268 hasPublicationYear "2021" @default.
• W4200416268 type Work @default.
• W4200416268 citedByCount "16" @default.
• W4200416268 countsByYear W42004162682022 @default.
• W4200416268 countsByYear W42004162682023 @default.
• W4200416268 crossrefType "journal-article" @default.
• W4200416268 hasAuthorship W4200416268A5002432376 @default.
• W4200416268 hasAuthorship W4200416268A5012265328 @default.
• W4200416268 hasAuthorship W4200416268A5026802895 @default.
• W4200416268 hasAuthorship W4200416268A5033719787 @default.
• W4200416268 hasAuthorship W4200416268A5046857018 @default.
• W4200416268 hasAuthorship W4200416268A5049187164 @default.
• W4200416268 hasAuthorship W4200416268A5056683017 @default.
• W4200416268 hasAuthorship W4200416268A5066028867 @default.
• W4200416268 hasAuthorship W4200416268A5068388301 @default.
• W4200416268 hasAuthorship W4200416268A5069553267 @default.
• W4200416268 hasAuthorship W4200416268A5076170209 @default.
• W4200416268 hasAuthorship W4200416268A5076522769 @default.
• W4200416268 hasAuthorship W4200416268A5077260044 @default.
• W4200416268 hasAuthorship W4200416268A5081498298 @default.
• W4200416268 hasAuthorship W4200416268A5084212600 @default.
• W4200416268 hasAuthorship W4200416268A5085954137 @default.
• W4200416268 hasAuthorship W4200416268A5090767185 @default.
• W4200416268 hasBestOaLocation W42004162681 @default.
• W4200416268 hasConcept C126322002 @default.
• W4200416268 hasConcept C159110408 @default.
• W4200416268 hasConcept C160735492 @default.
• W4200416268 hasConcept C162324750 @default.
• W4200416268 hasConcept C177713679 @default.
• W4200416268 hasConcept C197934379 @default.
• W4200416268 hasConcept C2777288759 @default.
• W4200416268 hasConcept C2779134260 @default.
• W4200416268 hasConcept C2779951463 @default.
• W4200416268 hasConcept C3019806175 @default.
• W4200416268 hasConcept C50522688 @default.
• W4200416268 hasConcept C71924100 @default.
• W4200416268 hasConceptScore W4200416268C126322002 @default.
• W4200416268 hasConceptScore W4200416268C159110408 @default.
• W4200416268 hasConceptScore W4200416268C160735492 @default.
• W4200416268 hasConceptScore W4200416268C162324750 @default.
• W4200416268 hasConceptScore W4200416268C177713679 @default.
• W4200416268 hasConceptScore W4200416268C197934379 @default.
• W4200416268 hasConceptScore W4200416268C2777288759 @default.
• W4200416268 hasConceptScore W4200416268C2779134260 @default.
• W4200416268 hasConceptScore W4200416268C2779951463 @default.
• W4200416268 hasConceptScore W4200416268C3019806175 @default.
• W4200416268 hasConceptScore W4200416268C50522688 @default.
• W4200416268 hasConceptScore W4200416268C71924100 @default.
• W4200416268 hasIssue "S17" @default.
• W4200416268 hasLocation W42004162681 @default.
• W4200416268 hasLocation W42004162682 @default.
• W4200416268 hasLocation W42004162683 @default.
• W4200416268 hasLocation W42004162684 @default.
• W4200416268 hasLocation W42004162685 @default.
• W4200416268 hasOpenAccess W4200416268 @default.
• W4200416268 hasPrimaryLocation W42004162681 @default.
• W4200416268 hasRelatedWork W1992426253 @default.
• W4200416268 hasRelatedWork W2151922639 @default.
• W4200416268 hasRelatedWork W2159406923 @default.
• W4200416268 hasRelatedWork W2417785652 @default.
• W4200416268 hasRelatedWork W2911677179 @default.
• W4200416268 hasRelatedWork W2915644342 @default.
• W4200416268 hasRelatedWork W3034286462 @default.
• W4200416268 hasRelatedWork W3166797618 @default.
• W4200416268 hasRelatedWork W4210913627 @default.
• W4200416268 hasRelatedWork W4288738052 @default.
• W4200416268 hasVolume "15" @default.
• W4200416268 isParatext "false" @default.
• W4200416268 isRetracted "false" @default.
• W4200416268 workType "article" @default.